BofA raised the firm’s price target on Liquidia (LQDA) to $37 from $35 and keeps a Buy rating on the shares. Based on Q3 pricing and volume trends for key drugs as well as relevant company commentary, the firm previewed Q3 EPS updates for its commercial-stage biopharma coverage, telling investors that it does not expect any major Q3 beats/misses and no big 2026 revisions among the group.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LQDA:
- Positive Outlook for Liquidia Technologies Amid Strong Sales and Strategic Developments
- BTIG biotech analyst holds an analyst/industry conference call
- Liquidia Technologies: Promising Growth and Market Expansion with Yutrepia
- Liquidia Technologies call volume above normal and directionally bullish
- Liquidia Technologies put volume heavy and directionally bearish